Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1drug Wegovy (semaglutide), as the US Food and Drug ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

Updated on: May 12, 2025 / 12:39 PM EDT / CBS News ...